title: What can we do to reduce the viral reservoir in HIV-1-infected individuals?
authors.affiliation: Center for AIDS Research, Department of Medicine, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Rangos 552, Baltimore, MD 21205, USA.
authors.forename: Christopher W
authors.initials: CW
authors.lastname: Pohlmeyer
authors.affiliation: Center for AIDS Research, Department of Medicine, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Rangos 552, Baltimore, MD 21205, USA.
authors.forename: Victoria E
authors.initials: VE
authors.lastname: Walker-Sperling
authors.affiliation: Center for AIDS Research, Department of Medicine, Johns Hopkins University School of Medicine, 855 N. Wolfe Street, Rangos 552, Baltimore, MD 21205, USA.
authors.forename: Joel N
authors.initials: JN
authors.lastname: Blankson
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D019562:Viral Load; D017735:Virus Latency / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents
keywords: AIDS; HIV; eradication; immunity